文献速递神经康复脊髓损伤康复

阴蒂真空吸引与振动刺激治疗神经源性女性性高潮障碍的随机试验

Randomized Trial of Clitoral Vacuum Suction Versus Vibratory Stimulation in Neurogenic Female Orgasmic Dysfunction.
PubMed 文献 · Arch Phys Med Rehabil · 2017-09-09

该随机临床试验纳入31例多发性硬化(MS)或脊髓损伤(SCI)女性,比较阴蒂真空吸引装置(CVSD)与振动刺激(V)治疗性高潮障碍的安全性和疗效。结果显示CVSD在FSFI总分及多个维度显著改善并降低性困扰,V仅在高潮子量表显著改善;CVSD疗效维持至治疗后4周。

要点

  • CVSD可显著改善MS/SCI女性性功能总分、欲望、唤起、润滑、高潮及满意度并降低困扰。
  • 振动刺激仅显著改善FSFI高潮子量表,且疗效限于治疗期。
  • 因可及性与成本,临床可考虑振动刺激;CVSD推荐用于多种性功能障碍或振动无效者。

核心结论

  • CVSD治疗MS和SCI相关女性神经源性性功能障碍安全且总体有效。
  • 振动刺激对神经源性性高潮障碍也安全有效,但结果仅限于积极治疗期。

研究设计与样本

  • 随机临床试验,在两家学术医疗中心开展,共纳入31例女性(20例MS,11例SCI)。
  • 干预为为期12周的CVSD与V使用比较。

主要发现

  • CVSD组FSFI总分(P=.011)、欲望(P=.009)、唤起(P=.009)、润滑(P=.008)、高潮(P=.012)、满意度(P=.049)均显著提高,FSDS困扰显著降低(P=.020)。
  • V组仅FSFI高潮子量表显著提高(P=.028)。
  • CVSD组在治疗结束后4周维持改善。

关键数值与推荐

  • 主要结局指标为女性性功能指数(FSFI)和女性性困扰量表(FSDS)。
  • CVSD组FSFI总分P=.011,欲望P=.009,唤起P=.009,润滑P=.008,高潮P=.012,满意度P=.049;FSDS P=.020。
  • V组FSFI高潮子量表P=.028。

临床怎么用

  • 因可及性与成本,临床医生可考虑对MS或SCI伴性高潮障碍的女性使用振动刺激。
  • CVSD推荐用于存在多种性功能障碍或振动刺激无效的女性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To examine the safety and efficacy of using a clitoral vacuum suction device (CVSD) versus vibratory stimulation (V) to treat orgasmic dysfunction in women with multiple sclerosis (MS) or spinal cord injury (SCI). DESIGN: Randomized clinical trial. SETTING: Two academic medical centers. PARTICIPANTS: Women (N=31) including 20 with MS and 11 with SCI. INTERVENTION: A 12-week trial of the use of a CVSD versus V. MAIN OUTCOME MEASURES: Female Sexual Function Inventory (FSFI) and Female Sexual Distress Scale (FSDS). RESULTS: Twenty-three women (18 MS, 5 SCI) completed the study including 13 of 16 randomized to CVSD and 10 of 15 randomized to V. There was a statistically significant increase in total FSFI score (P=.011), desire (P=.009), arousal (P=.009), lubrication (P=.008), orgasm (P=.012), and satisfaction (P=.049), and a significant decrease in distress as measured by FSDS (P=.020) in subjects using the CVSD. In subjects who used V, there was a statistically significant increase in the orgasm subscale of the FSFI (P=.028). Subjects using the CVSD maintained improvements 4 weeks after treatment. CONCLUSIONS: CVSD is safe and overall efficacious to treat female neurogenic sexual dysfunction related to MS and SCI. V is also safe and efficacious for female neurogenic orgasmic dysfunction; however, results were limited to the active treatment period. Because of ease of access and cost, clinicians can consider use of V for women with MS or SCI with orgasmic dysfunction. CVSD is recommended for women with multiple sexual dysfunctions or for whom V is ineffective.

来源:Arch Phys Med Rehabil,查看原文。版权归原作者所有。

引用

  1. Alexander M, Bashir K, Alexander C, et al. Randomized Trial of Clitoral Vacuum Suction Versus Vibratory Stimulation in Neurogenic Female Orgasmic Dysfunction. Arch Phys Med Rehabil. 2017. PMID: 28899827. doi:10.1016/j.apmr.2017.09.001

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。